Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules

PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Dupuytren's Disease
Interventions
BIOLOGICAL

Collagenase clostridium histolyticum

Single injection into nodule

BIOLOGICAL

Placebo

Single injection into nodule

Trial Locations (11)

4000

Brisbane Hand & Upper Limb Clinic, Brisbane

4021

Houston Medical, Kippa-Ring

11794

State University of New York, Stony Brook

16602

Blair Orthopedic Associates, Inc., Altoona

28207

OrthoCarolina Research Institute, Inc., Charlotte

46260

Indiana Hand to Shoulder Center, Indianapolis

73109

Orthopedic and Reconstructive Center, Oklahoma City

85712

Tucson Orthopaedic Institute, Tucson

92024

CORE Orthopaedic Medical Center, Encinitas

92563

Brigid Freyne, MD, Inc., Murrieta

94904

Marin Endocrine Care & Research, Inc., Greenbrae

Sponsors
All Listed Sponsors
lead

Endo Pharmaceuticals

INDUSTRY